Pacific Biosciences, a US-based gene sequencing company, hit the mid-point of its flotation price range to raise $186m after fees, according to a regulatory filing.
The company priced 12.5 million common shares at $16 each compared to $15 to $17 it set ahead of its initial public offering, and had a market capitalization of $802m on the Nasdaq stock exchange.
Existing shareholders, including four strategic investors, are locked-up from selling shares for 180 days and so will be diluted by the initial public offering of new shares.
Pacific closed its series F round at $109m last month, including $50m from peer Gen-Probe at $7.63 per share to own 8.6%. The series E round, which closed the year before, raised $188m at $7 per share, with more than $20m coming from both Intel Capital, the corporate venturing unit of semiconductor company Intel, and Wellcome Trust, a UK-based medical endowment.
Alongside multiple VCs, the final strategic is agriculture company Monsanto.
The VCs are Mohr Davidow Ventures (12%), Kleiner Perkins Caufield and Byers (9.7%), Maverick Capital (9.1%), Alloy Ventures (6.9%), Blackstone Cleantech Venture Partners (6.3%), Deerfield Management (5.3%), Sutter Hill Ventures, Morgan Stanley, Redmile Group, T Rowe Price, AllianceBernstein, DAG Ventures and Teachers’ Private Capital.
In total the company has raised about $460m, according to news provider Fortune.